Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme implicated in the negative regulation of insulin and leptin signaling. By inhibiting PTP1B activity, this molecule has been investigated as a potential therapeutic agent for metabolic disorders such as type 2 diabetes and obesity. It features a benzofuran core substituted with dibromohydroxybenzoyl and sulfamoylphenyl groups. The compound is primarily used in research settings to study the modulation of PTP1B activity and its downstream effects on cellular signaling pathways[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N-(4-sulfamoylphenyl)-1-benzofuran-6-sulfonamide.